Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

Abstract Background Melanoma is a rare, deadly disease without effective treatment options in China. Vemurafenib is a selective inhibitor of oncogenic BRAF V600 kinase approved in more than 90 countries, based on results obtained primarily in Caucasian patients. Limited data are available regarding...

Full description

Bibliographic Details
Main Authors: Lu Si, Xiaoshi Zhang, Zhen Xu, Qiudi Jiang, Lilian Bu, Xuan Wang, Lili Mao, Weijiang Zhang, Nicole Richie, Jun Guo
Format: Article
Language:English
Published: BMC 2018-05-01
Series:BMC Cancer
Subjects:
BRAF V600-positive
Advanced melanoma
Vemurafenib
China
Asia
Online Access:http://link.springer.com/article/10.1186/s12885-018-4336-3

Internet

http://link.springer.com/article/10.1186/s12885-018-4336-3

Similar Items